The University of Southampton
University of Southampton Institutional Repository

Resilience as a predictor of treatment response in posttraumatic stress disorder patients treated with venlafaxine extended release or placebo

Resilience as a predictor of treatment response in posttraumatic stress disorder patients treated with venlafaxine extended release or placebo
Resilience as a predictor of treatment response in posttraumatic stress disorder patients treated with venlafaxine extended release or placebo
This post-hoc analysis evaluated resilience as a predictor of treatment response in patients with posttraumatic stress disorder (PTSD). Data were pooled from two randomized, double-blind studies conducted with adult outpatients treated with flexible doses of venlafaxine extended release (ER) 37.5 to 300 mg/day or placebo. The 17-item Clinician-Administered Posttraumatic Stress Disorder Scale (CAPS-SX(17)) was the primary outcome measure. Baseline Connor-Davidson Resilience Scale (CD-RISC) scores for the 25-, 10-, and 2-item versions were used to predict changes in PTSD symptom severity at week 12 and symptomatic remission (CAPS-SX(17) ? 20). Analyses were conducted for the overall population and separately for the individual treatment groups. In total, pretreatment resilience predicted a positive treatment response. For the overall population, all versions of the CD-RISC predicted CAPS-SX(17) change scores and remission after controlling for variables such as treatment group and baseline symptom severity. For venlafaxine ER-treated patients, all versions of the CD-RISC were predictive of remission, but only the 10-item version was predictive of CAPS-SX(17) change score. Our results suggest that higher pretreatment resilience is generally associated with a positive treatment response. Future research may be warranted to explore the relationship between response to active treatment and the spectrum of resiliency.
posttraumatic stress disorder, remission, resilience, venlafaxine extended release
0269-8811
778-783
Davidson, Jonathan
3ee9aa6d-9112-4e56-950a-74869aebfb24
Stein, Dan J.
07cf0cbd-837d-49ac-aceb-1c393a2f3e00
Rothbaum, Barbara O.
d34b0e10-6c38-4199-8b20-62f792f6d020
Pedersen, Ron
bb3776f0-8051-498e-96b3-940642e3ba5b
Szumski, Annette
6e326e2a-2ad2-47b5-9d83-9ae9a3ae7b52
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Davidson, Jonathan
3ee9aa6d-9112-4e56-950a-74869aebfb24
Stein, Dan J.
07cf0cbd-837d-49ac-aceb-1c393a2f3e00
Rothbaum, Barbara O.
d34b0e10-6c38-4199-8b20-62f792f6d020
Pedersen, Ron
bb3776f0-8051-498e-96b3-940642e3ba5b
Szumski, Annette
6e326e2a-2ad2-47b5-9d83-9ae9a3ae7b52
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e

Davidson, Jonathan, Stein, Dan J., Rothbaum, Barbara O., Pedersen, Ron, Szumski, Annette and Baldwin, David S. (2012) Resilience as a predictor of treatment response in posttraumatic stress disorder patients treated with venlafaxine extended release or placebo. Journal of Psychopharmacology, 26 (6), 778-783. (doi:10.1177/0269881111413821). (PMID:21926426)

Record type: Article

Abstract

This post-hoc analysis evaluated resilience as a predictor of treatment response in patients with posttraumatic stress disorder (PTSD). Data were pooled from two randomized, double-blind studies conducted with adult outpatients treated with flexible doses of venlafaxine extended release (ER) 37.5 to 300 mg/day or placebo. The 17-item Clinician-Administered Posttraumatic Stress Disorder Scale (CAPS-SX(17)) was the primary outcome measure. Baseline Connor-Davidson Resilience Scale (CD-RISC) scores for the 25-, 10-, and 2-item versions were used to predict changes in PTSD symptom severity at week 12 and symptomatic remission (CAPS-SX(17) ? 20). Analyses were conducted for the overall population and separately for the individual treatment groups. In total, pretreatment resilience predicted a positive treatment response. For the overall population, all versions of the CD-RISC predicted CAPS-SX(17) change scores and remission after controlling for variables such as treatment group and baseline symptom severity. For venlafaxine ER-treated patients, all versions of the CD-RISC were predictive of remission, but only the 10-item version was predictive of CAPS-SX(17) change score. Our results suggest that higher pretreatment resilience is generally associated with a positive treatment response. Future research may be warranted to explore the relationship between response to active treatment and the spectrum of resiliency.

Full text not available from this repository.

More information

e-pub ahead of print date: 17 September 2011
Published date: June 2012
Keywords: posttraumatic stress disorder, remission, resilience, venlafaxine extended release
Organisations: Faculty of Medicine, Clinical Neurosciences

Identifiers

Local EPrints ID: 182465
URI: http://eprints.soton.ac.uk/id/eprint/182465
ISSN: 0269-8811
PURE UUID: 0051d98b-349f-4b77-a175-00b68d86239f
ORCID for David S. Baldwin: ORCID iD orcid.org/0000-0003-3343-0907

Catalogue record

Date deposited: 19 Apr 2011 10:26
Last modified: 18 Feb 2021 16:44

Export record

Altmetrics

Contributors

Author: Jonathan Davidson
Author: Dan J. Stein
Author: Barbara O. Rothbaum
Author: Ron Pedersen
Author: Annette Szumski

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×